Navigation Links
Nanoparticle-based battlefield pain treatment moves a step closer
Date:9/24/2009

Ann Arbor, Mich. University of Michigan scientists have developed a combination drug that promises a safer, more precise way for medics and fellow soldiers in battle situations to give a fallen soldier both morphine and a drug that limits morphine's dangerous side effects.

They use nanotechnology to devise ultra-small polymer particles capable of carrying the drugs into the body. The development of the combination drug makes possible a precise feedback system that can safely regulate release of the drugs aboard the nanoparticles.

The scientists at the Michigan Nanotechnology Institute for Medicine and Biological Sciences report their results in the September issue of Bioorganic & Medicinal Chemistry Letters.

Context

Soldiers injured in combat typically receive morphine as soon as possible to relieve pain. Morphine, however, also depresses normal breathing and blood pressure, sometimes to life-threatening levels. So medics need to give a short-acting drug that aids normal respiration and heart beat, but in doses that still allow the morphine to relieve pain effectively. Today, achieving that balance is a challenge outside a hospital.

The combination drug that U-M scientists have developed promises to make balanced treatment possible even in combat zones, says James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences (MNIMBS) and the study's senior author.

"This system could improve pain management for millions of patients with chronic illnesses," says Baker, Ruth Dow Doan Professor and allergy division chief in the U-M Department of Internal Medicine.

The long-range goal of the research, funded by the U.S. Defense Advanced Research Projects Agency, is to develop a practical method that medics or soldiers themselves could administer, perhaps using an auto-injector device.

Research details

U-M chemists screened several compounds to search for a successful "pro drug," a drug that can release or become another drug. In this case, they wanted one that could convert to Naloxone, a drug now used to counter morphine's effects, but would activate only when blood oxygen levels drop too low. In laboratory tests using human plasma, one pro drug successfully sensed oxygen levels and turned on or off as needed.

"When respiratory distress is too severe, that will trigger release of Naloxone, the antagonist (morphine-suppressing) drug. When the oxygen blood levels go up, that will stop the action of the antagonist drug and more morphine will be available," says Baohua Huang, Ph.D., the study's first author and a research investigator at the Michigan Nanotechnology Institute and in Internal Medicine.

What's next

MNIMBS scientists are proceeding with animal studies of the pro drug's effects and will develop a dendrimer that can carry the pro drug and morphine, using a dendrimer platform technology previously developed at U-M. They hope to advance to more animal and eventually human studies.


'/>"/>

Contact: Anne Rueter
arueter@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related biology news :

1. Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
2. Rethinking Alzheimers disease and its treatment targets
3. Diabetes drug kills cancer stem cells in combination treatment in mice
4. UCF discovery could open door to obesity, diabetes treatments
5. Mothers immune system may block fetal treatments for blood diseases
6. Protein handlers should be effective treatment target for cancer and Alzheimers
7. Experimental treatment halts hypoxic-ischemic brain injury in newborns
8. Discovery to aid in future treatments of third-world parasites
9. ISU researchers find possible treatment for spinal muscular atrophy
10. Promising new treatment for Alzheimers suggested based on Hebrew University research
11. New technique can fast-track better ionic liquids for biomass pre-treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... 12, 2016 WearablesResearch.com , a brand ... overview results from the Q1 wave of its quarterly ... was consumers, receptivity to a program where they would ... health insurance company. "We were surprised to ... Michael LaColla , CEO of Troubadour Research, "primarily ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
Breaking Biology Technology: